Neurocrine Biosciences
NBIX
#1459
Rank
S$20.13 B
Marketcap
S$198.11
Share price
-0.43%
Change (1 day)
11.85%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Earnings for Neurocrine Biosciences (NBIX)

Earnings in 2026 (TTM): S$1.02 Billion

According to Neurocrine Biosciences 's latest financial reports the company's current earnings are S$3.10 Billion. In 2025 the company made an earning of S$0.80 Billion, an increase over its 2024 earnings that were of S$0.77 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Neurocrine Biosciences from 1996 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) S$1.02 B26.77%
2025 S$0.80 B3.9%
2024 S$0.77 B96.41%
2023 S$0.39 B41.13%
2022 S$0.28 B73.74%
2021 S$0.16 B-8.82%
2020 S$0.17 B77.78%
2019 S$99.7 M49.83%
2018 S$66.54 M-142.57%
2017 -S$0.16 Billion-14.73%
2016 -S$0.19 Billion53.15%
2015 -S$0.12 Billion46.25%
2014 -S$81.85 Million29.66%
2013 -S$63.13 Million-3530.8%
2012 S$1.83 M-95.73%
2011 S$43.1 M
2009 -S$60.59 Million-45.38%
2008 -S$0.12 Billion-58.87%
2007 -S$0.27 Billion87.3%
2006 -S$0.15 Billion351.97%
2005 -S$31.86 Million-52.09%
2004 -S$66.5 Million-10.98%
2003 -S$74.7 Million
2001 -S$55.76 Million
1999 -S$25.15 Million108.32%
1998 -S$12.08 Million
1996 S$3.68 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Pfizer
PFE
S$13.45 B 1,225.86%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
S$7.59 B 648.00%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
S$39.54 B 3,796.47%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
S$99.17 M-90.23%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-S$53.07 Million-105.23%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
S$0.14 B-85.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
-S$7.94 Million-100.78%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
S$2.15 B 112.21%๐Ÿ‡ฌ๐Ÿ‡ง UK